659 A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors
Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A756-A756
10.1136/jitc-2024-sitc2024.0659